Scientists at Aten Porus Lifesciences Pvt Ltd. and Avammune Therapeutics Inc. have synthesized double-stranded RNA-specific adenosine deaminase (ADAR; ADAR1; IFI-4) inhibitors reported to be useful for the treatment of cancer.
Di’ao Group Chengdu Pharmaceutical Co Ltd. has disclosed DNA-directed RNA polymerase, mitochondrial (POLRMT; MtRPOL) inhibitors reported to be useful for the treatment of cancer.
Circle Pharma Inc. has submitted an IND application to the FDA for CID-078, a first-in-class cyclin A/B RxL inhibitor. Pending approval, the company plans to initiate a phase I trial in patients with advanced solid tumor malignancies.
SCG Cell Therapy Pte Ltd. has gained FDA clearance of its IND application to initiate a phase I/II trial of SCG-142, a novel next-generation human papillomavirus (HPV) E7-specific T-cell receptor-engineered T (TCR T)-cell therapy for patients with HPV-associated solid tumors.
Waypoint Bio has raised $14.5 million in seed funding to support its work pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology.
“Do dreams predict the future?” Abidemi Otaiku asked his audience at the 10th Congress of the European Academy of Neurology, currently being held in Helsinki. Most audience members, being hard-boiled scientists, did not believe they did. But Otaiku, whose work won the award for best clinical abstract at the conference, presented data indicating that in some cases, they can.
Shenyang Pharmaceutical University has identified serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer.
Hainan Simcere Pharmaceutical Co. Ltd. has patented fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of cancer.
RSS
